Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $2,138.15 today based on a price of $325.64 for ALNY at the time of writing.

Some genetically targeted therapies are classified in the IRA as small-molecule drugs, limiting the incentive for biotech ...

Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

The pharmaceutical industry has a fresh sense of direction after President Donald Trump’s tax-and-spending law included a ...

The Invesco Biotechnology & Genome ETF (PBE) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market. For a ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Roche reported better than expected first-half operating profit, driven by strong sales of breast cancer and asthma ...

Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the ...